Combining protein arginine methyltransferase inhibitor and anti-programmed death-ligand-1 inhibits pancreatic cancer progression

Figure 3 PT1001B enhances antitumor immunity. Cell suspensions were prepared from pancreatic tumor tissues and spleens from the four groups of tumor-bearing mice and stained with CD45-, CD4-, CD8-, PD-L1-, and PD-1-specific antibodies. Stained cells were analyzed by flow cytometry. The left panel presents representative images, and the right panel shows the statistical analysis. A: Analysis of CD45-/PD-L1+ cells in the tumors; B: Analysis of CD45+/PD-1+ cells in the tumors; C: Analysis of CD45+/PD-1+ cells in the spleens; D: Analysis of CD4+ T cells and CD8+ T cells in the tumors; E: Analysis of CD4+ T cells and CD8+ T cells in the spleens. Differences in the percentages of cells were analyzed by one-way ANOVA. Data represent the mean ± SE (n = 4). ^aP < 0.05, ^bP < 0.01 vs control group; ^cP < 0.05, ^dP < 0.01 vs anti-PD-L1 group. PD-L1: Programmed death-ligand-1; PD-1: Programmed death-1.